Summary of Pharmaron (3759.HK) Earnings Review Company Overview - **Company**: Pharmaron (3759.HK) - **Market Cap**: HK$33.4 billion / $4.3 billion - **Enterprise Value**: HK$38.9 billion / $5.0 billion - **Current Price**: HK$18.82 - **12-Month Price Target**: HK$31.00 (Upside: 64.7%) [1][6] Financial Performance - **4Q25 Revenue Growth**: +16% year-over-year (y/y) [1] - **4Q25 Non-IFRS Net Profit Growth**: +18% y/y [1] - **Margins**: Sequential improvement in margins through 2025, with non-IFRS net margins of 11.3%, 12.2%, 12.9%, and 14.7% for 1Q-4Q25 [1] - **New Orders**: Total new orders increased by approximately 14% y/y, driven by laboratory services (+12% y/y) and small-molecule D&M (+13% y/y) [1] Revenue Guidance - **FY26 Revenue Growth Guidance**: Expected to grow by 12-18% y/y, factoring in an assumed 3% depreciation of the US dollar [1] Segment Review Laboratory Services - **4Q25 Revenue Growth**: +17.9% y/y, with a gross margin of 44.3% [3] - **Bioscience Contribution**: Over 56% of segment revenue [3] - **Investments**: Enhancements in service capabilities through AI and automation [3] Small-Molecule CDMO - **4Q25 Revenue Growth**: +17.6% y/y, gross margin improved to 37.8% from 34.2% in 3Q [18] - **New Large-Scale Production Order**: Signed in 1Q26 [18] Clinical Development - **4Q25 Revenue Decline**: -0.7% y/y, gross margin at 10.3% [18] - **Pricing Pressure**: Indications of stabilization in pricing [18] Biologics & CGT - **Revenue Growth**: +43.4% y/y, with gross margin improving sequentially [18] Strategic Partnerships - **Cooperation with Eli Lilly**: Near-term revenue contribution will take time due to technology transfer and validation work; highlights long-term structural opportunities in localized manufacturing in China [2] Valuation and Risks - **Target Price Adjustments**: Fine-tuned net profit estimates for 2026E-28E by +0.1%, +1.0%, +2.3% [17] - **Key Upside Risks**: 1. Accelerated revenue conversion from increased customer engagement 2. Better-than-expected facilities ramp-up 3. Improved profitability for CGT business [17] - **Downside Risks**: 1. Escalation in US-China trade tensions 2. Growing labor costs and talent retention challenges 3. Slowdown in global pharma R&D spending [17] Conclusion Pharmaron is positioned for growth with solid revenue guidance and strategic partnerships, although it faces potential risks from external market conditions and internal operational challenges. The company continues to enhance its service capabilities and expand its market presence, particularly in the laboratory services and small-molecule CDMO segments.

Investment Rating - The investment rating for the company is "Accumulate" [2][7] Core Views - The company reported a revenue of 6.67 billion yuan for 2025, representing a year-on-year growth of 14.91%, with a net profit attributable to shareholders of 1.13 billion yuan, up 19.35% year-on-year [2][3] - The company has a strong order backlog, with significant growth in emerging businesses, particularly in the CDMO (Contract Development and Manufacturing Organization) sector [3][4] - The company expects revenue growth to accelerate in 2026, with guidance indicating a revenue increase of 19%-22% [6] Financial Performance - In 2025, the company achieved a gross margin of 42.0%, a slight decrease of 0.4 percentage points year-on-year, primarily due to the increased proportion of lower-margin emerging businesses [4] - The company’s R&D investment for 2025 was 593 million yuan, reflecting a commitment to exploring and applying cutting-edge technologies [4] - The net profit for 2026 is projected to be 1.42 billion yuan, with an EPS of 3.93 yuan per share, corresponding to a PE ratio of 28.20 times [7][10] Business Segments - The small molecule CDMO segment generated revenue of 4.735 billion yuan in 2025, with a year-on-year growth of 3.59% [3] - Emerging businesses saw a revenue increase of 57.30% in 2025, with international revenue growing over 240% [3] - The company has a robust pipeline with 294 ongoing clinical research projects, including 122 in Phase II and beyond [3][4]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2][4]. Core Views - The company is experiencing high-quality revenue and profit growth, entering an accelerated growth cycle due to multiple sectors' favorable conditions [4]. - In 2025, the company achieved a revenue of 6.67 billion yuan, a year-on-year increase of 14.91%, and a net profit attributable to shareholders of 1.13 billion yuan, up 19.35% year-on-year [4]. - The adjusted net profit for 2025 was 1.25 billion yuan, reflecting a significant increase of 56.09% year-on-year, with an adjusted net profit margin of 18.8%, up approximately 5.0 percentage points [4]. - The company’s order backlog reached 1.385 billion USD by the end of 2025, a year-on-year growth of 31.65%, indicating a strong demand outlook [4]. Financial Summary - The company’s revenue is projected to grow from 8.07 billion yuan in 2026 to 12.17 billion yuan in 2028, with year-on-year growth rates of 21.0% and 23.0% respectively [7]. - The net profit attributable to shareholders is expected to increase from 1.51 billion yuan in 2026 to 2.31 billion yuan in 2028, with year-on-year growth rates of 33.0% and 24.4% respectively [7]. - The company’s gross margin is projected to improve from 42.8% in 2026 to 44.6% in 2028, while the net profit margin is expected to rise from 18.7% to 19.0% over the same period [7]. - The earnings per share (EPS) is forecasted to grow from 4.18 yuan in 2026 to 6.41 yuan in 2028, with corresponding price-to-earnings (P/E) ratios decreasing from 24.1 to 15.7 [7]. Business Performance - The small molecule CDMO segment generated revenue of 4.735 billion yuan in 2025, a year-on-year increase of 3.59%, with a gross margin of 46.83% [5]. - The chemical macromolecule CDMO business saw rapid growth, achieving revenue of 1.028 billion yuan in 2025, up 123.72% year-on-year, with a significant increase in order backlog [5]. - The biopharmaceutical CDMO business also showed strong momentum, with revenue growth of 95.76% year-on-year and a substantial increase in order backlog [5]. - The company is expected to enter an accelerated growth phase in 2026, driven by the approval and market release of several blockbuster drugs [5].

Core Viewpoint - The company's 2025 performance aligns with expectations, showing a revenue increase but a decline in net profit due to high comparative figures from 2024 [1] Group 1: Financial Performance - In 2025, the company reported revenue of 14.095 billion, a year-on-year increase of 14.8% [1] - The net profit attributable to shareholders was 1.664 billion, a year-on-year decrease of 7.2%, primarily due to high investment gains from equity disposals in 2024 [1] - Adjusted net profit reached 1.816 billion, reflecting a year-on-year increase of 13.0% [1] Group 2: Business Development Trends - The laboratory services segment experienced robust growth, with revenue of 8.159 billion in 2025, up 15.78% year-on-year, and a gross margin of 45.10%, an increase of 0.18 percentage points [2] - Revenue from the top 20 global pharmaceutical clients grew by 29.37%, increasing their revenue contribution to 20.09% [2] - The small molecule CDMO segment achieved revenue of 3.483 billion, a year-on-year increase of 16.53%, with a gross margin of 34.31%, up 0.69 percentage points [2] - The company successfully launched its first commercial API production project for the U.S. market in Q4 2025 and signed a strategic cooperation agreement with Eli Lilly for the commercialization of an oral small molecule GLP-1 receptor agonist [2] Group 3: Profit Forecast and Valuation - The company maintains its profit forecasts for 2026 and 2027, with current A-share prices corresponding to 25.6x and 20.5x P/E ratios for 2026 and 2027, respectively [3] - The A-share target price is set at 35.00, implying a 25.1% upside potential from the current price [3] - The H-share target price is set at 26.00 HKD, indicating a 38.2% upside potential from the current price [3]

Core Viewpoint - The company announced a revenue target of 6.67 billion yuan for 2025, representing a year-over-year increase of 14.9%, and a net profit attributable to shareholders of 1.133 billion yuan, up 19.3% year-over-year [1] Group 1: Financial Performance - The company achieved a revenue of 2.04 billion yuan in Q4, reflecting a year-over-year growth of 22.6%, and a constant currency growth of 30.8% [1] - The adjusted net profit attributable to shareholders for 2025 is projected at 1.253 billion yuan, showing a significant year-over-year increase of 56.15% [1] - The overall gross margin for 2025 is expected to be 42%, with the small molecule business maintaining a high gross margin of 46.8% [3] Group 2: Business Segments - Revenue from the small molecule CDMO segment is projected at 4.735 billion yuan, with a year-over-year growth of 3.59% [2] - Emerging businesses are expected to generate 1.929 billion yuan in revenue, marking a substantial year-over-year increase of 57.3%, driven by significant growth in chemical and biological macromolecules [2] - The revenue from chemical macromolecules is anticipated to reach 1.028 billion yuan, with a remarkable year-over-year growth of 123.72% [2] Group 3: Future Guidance - The company expects revenue growth of 19-22% for 2026, indicating a notable acceleration compared to 2025 [2] - The backlog of orders for 2025 is projected at 1.385 billion USD, reflecting a year-over-year increase of 31.65%, with emerging businesses being the main driver [2] - Capital expenditures (CAPEX) are expected to reach 2.1 billion yuan in 2026, representing a year-over-year increase of 65% [2] Group 4: Profitability and Cost Management - The company anticipates further improvement in profitability as emerging businesses expand, with the gross margin for emerging businesses expected to rise to 30.1%, an increase of 8.4 percentage points [3] - The operating expense ratio is projected to decrease slightly to 22.53% in 2025, down 0.77 percentage points year-over-year [3] - The company forecasts net profits of 1.448 billion yuan, 1.939 billion yuan, and 2.503 billion yuan for 2026, 2027, and 2028, respectively, with year-over-year growth rates of 27.82%, 33.92%, and 29.13% [3]

Investment Rating - The investment rating for the company is "Accumulate" with a target price of 177.30 CNY [6][12]. Core Insights - The company, WuXi AppTec, is a leading global CRDMO player, with its 2025 performance exceeding guidance, showing a significant profit margin increase. The Tides business is strong, with a backlog of orders increasing by 28% by the end of 2025, and a projected revenue growth of 18-22% for 2026 [2][12]. Financial Summary - Total revenue for 2025 was 45,456 million CNY, a year-on-year increase of 15.8%, surpassing the revised guidance. The net profit attributable to shareholders reached 19,151 million CNY, up 102.6% year-on-year. The adjusted Non-IFRS net profit was 14,960 million CNY, reflecting a 41.3% increase [4][12]. - The company forecasts revenues of 52,405 million CNY, 60,176 million CNY, and 66,900 million CNY for 2026, 2027, and 2028, respectively, with growth rates of 15.3%, 14.8%, and 11.2%. The net profit attributable to shareholders is expected to be 17,638 million CNY, 20,442 million CNY, and 22,375 million CNY for the same years, with growth rates of -7.9%, 15.9%, and 9.5% [12][13]. - The adjusted Non-IFRS gross margin improved to 48.2%, a year-on-year increase of 6.6 percentage points, driven by higher capacity utilization and an increase in high-margin business [12]. Business Performance - The chemical business generated revenue of 36,470 million CNY, a 25.5% year-on-year increase. The small molecule CDMO pipeline expanded, with revenue from small molecule D&M business reaching 19,920 million CNY, up 11.4% year-on-year [12]. - The Tides business saw revenue of 11,370 million CNY, a remarkable growth of 96% year-on-year, with a backlog of orders increasing by 20.2%. The number of clients for TIDES D&M services rose by 25%, and the number of service molecules increased by 45% [12].

Investment Rating - The investment rating for the company is "Accumulate" with a target price of 177.30 CNY [6][12]. Core Insights - The company, WuXi AppTec, is a leading global CRDMO player, with its 2025 annual performance exceeding guidance, showing a significant profit margin increase. The Tides business is strong, with a backlog of orders increasing by 28% as of the end of 2025, and a projected revenue growth of 18-22% for 2026 [2][12]. Financial Summary - Total revenue for 2025 was 45,456 million CNY, a year-on-year increase of 15.8%, surpassing the revised revenue guidance. The net profit attributable to shareholders was 19,151 million CNY, up 102.6% year-on-year. The adjusted Non-IFRS net profit was 14,960 million CNY, reflecting a 41.3% increase [4][12]. - The company expects revenues for 2026 to be between 52,405 million CNY and 53,000 million CNY, with a growth rate of 15.3% [12]. - The gross margin for adjusted Non-IFRS increased to 48.2%, up 6.6 percentage points year-on-year, driven by improved capacity utilization and a higher proportion of high-margin businesses [12]. Business Segments - The chemical business generated revenue of 36,470 million CNY in 2025, a 25.5% increase. The small molecule CDMO pipeline continues to expand, with 199,200 million CNY in revenue, an 11.4% increase, and a total of 3,452 molecules in the pipeline [12]. - The Tides business saw revenue of 11,370 million CNY in 2025, a remarkable 96% increase, with a backlog of orders growing by 20.2% [12]. Future Projections - For 2026-2028, the company forecasts revenues of 52,405 million CNY, 60,176 million CNY, and 66,900 million CNY, with growth rates of 15.3%, 14.8%, and 11.2% respectively. The net profit attributable to shareholders is projected to be 17,638 million CNY, 20,442 million CNY, and 22,375 million CNY for the same years, with growth rates of -7.9%, 15.9%, and 9.5% respectively [12][13].

Investment Rating - The investment rating for the company is "Buy" (maintained) for both A-shares and H-shares [7]. Core Insights - The company reported a revenue of 45.456 billion RMB for 2025, representing a year-over-year increase of 15.84%. The net profit attributable to shareholders was 19.151 billion RMB, up 102.65% year-over-year, and the adjusted non-IFRS net profit was 14.957 billion RMB, reflecting a 41.33% increase [1][5]. - The company expects a revenue growth guidance of 18-22% for 2026, supported by a strong order backlog and anticipated acceleration in growth for 2026-2027 [2][3]. - The TIDES business segment is projected to maintain high growth, with a revenue of 36.47 billion RMB in 2025, marking a 25.5% year-over-year increase, driven by a significant rise in orders and customer engagement [3][4]. Summary by Sections Financial Performance - For 2025, the company achieved a revenue of 45.456 billion RMB, with a net profit of 19.151 billion RMB, and an adjusted non-IFRS net profit of 14.957 billion RMB [1][5]. - The company anticipates revenues of 51.3-53 billion RMB for 2026, with a continued focus on maintaining a stable adjusted non-IFRS net profit margin [2]. Business Segments - WuXi Chemistry's revenue for 2025 is expected to reach 36.47 billion RMB, with a non-IFRS gross margin of 52.3%, driven by the TIDES segment's growth [3]. - The WuXi Testing and WuXi Biology segments are projected to stabilize, with revenues of 4.04 billion RMB and 2.68 billion RMB respectively for 2025, and expected growth rates of around 10% for 2026 [4]. Valuation and Estimates - The company is valued at 334.81 billion RMB for A-shares and 381.7 billion HKD for H-shares, with a target price of 112.21 RMB and 127.93 HKD respectively [5][12]. - The earnings per share (EPS) estimates for 2026, 2027, and 2028 are projected to be 5.66 RMB, 6.72 RMB, and 7.88 RMB respectively, reflecting an upward adjustment due to better-than-expected growth in the TIDES segment [5][11].

Investment Rating - The investment rating for the company is "Buy" (maintained) for both A-shares and H-shares [7]. Core Views - The company reported a revenue of 45.456 billion RMB for 2025, representing a year-over-year increase of 15.84%. The net profit attributable to shareholders was 19.151 billion RMB, up 102.65% year-over-year, and the adjusted non-IFRS net profit was 14.957 billion RMB, reflecting a 41.33% increase [1][5]. - The company expects a revenue growth guidance of 18-22% for its continuing operations in 2026, supported by a strong order backlog [2][3]. - The TIDES business segment is projected to maintain high growth, with a revenue increase of 96.0% year-over-year in 2025, contributing significantly to the overall revenue growth [3][4]. Summary by Sections Financial Performance - In Q4 2025, the company achieved a revenue of 12.599 billion RMB, a 9.19% increase year-over-year, and a net profit of 7.075 billion RMB, up 142.52% year-over-year [1]. - The gross margin for 2025 improved by 6.2 percentage points year-over-year, driven by a higher proportion of high-margin revenue [1]. Business Segments - WuXi Chemistry's revenue for 2025 was 36.47 billion RMB, with an adjusted non-IFRS gross margin of 52.3%, indicating a strong performance in the small molecule CDMO and TIDES segments [3]. - The WuXi Testing and WuXi Biology segments are expected to stabilize, with projected revenue growth rates of around 10% and high single-digit growth, respectively, in 2026 [4]. Profitability and Valuation - The company’s projected net profits for 2026-2028 are 16.887 billion RMB, 20.065 billion RMB, and 23.517 billion RMB, respectively, with corresponding EPS estimates of 5.66 RMB, 6.72 RMB, and 7.88 RMB [5][11]. - The company is valued at 334.81 billion RMB for A-shares and 381.70 billion HKD for H-shares, with target prices set at 112.21 RMB and 127.93 HKD, respectively [5][12].

Group 1: Business Operations - The company's plant protection business has reached a bottom in inventory reduction, and future operations are expected to stabilize [1] - The company maintains a long-term partnership with clients, focusing on a CDMO business model for the production of advanced intermediates [1] - The company plans to invest $200 million in the construction of its Malaysia base, with the first phase expected to be completed by the end of 2026 [4] Group 2: New Energy Sector - The company primarily sells LiFSI, cathode materials, and electrolyte products, with plans to strengthen existing products in 2026 [3] - The lithium hexafluorophosphate product is undergoing technical improvements, with commercialization expected in 2026 [3] - The company aims to expand its new energy product range and market presence, leveraging its R&D and production capabilities [3] Group 3: Pharmaceutical Business - The pharmaceutical sector has shown steady growth, with a focus on large clients and CDMO business models [5] - The company is actively expanding its client base and developing new projects in the pharmaceutical sector [5] - The company is investing in R&D to enhance its technical capabilities, exploring new areas such as amino acids and peptides [6] Group 4: Client Dependency and Market Strategy - The company acknowledges a high client concentration but emphasizes the importance of maintaining strong relationships with existing clients while seeking new ones [6][7] - The company believes that focusing on existing clients and expanding the customer base fosters mutual trust and sustainable cooperation [7] Group 5: Financial Outlook and Capital Expenditure - The company has no immediate plans for capital operations in the secondary market, focusing instead on investments in its coastal and Malaysian bases [7] - The net cash flow from operating activities for the first three quarters of 2025 is approximately 1 billion, sufficient to support planned capital expenditures [7] - Exchange rate gains and losses are expected to continue affecting net profits, with significant USD revenues and hedging activities in place [7]